SGI-1252 Compound for Muscle Wasting Disorders ID: 2013-061
A novel compound designed to combat muscle wasting disorders by inhibiting myostatin signaling.
Photo by starlineart - stock.adobe.com
Technology Overview
SGI-1252 is a small molecule inhibitor targeting the activin type IIB receptor (ACVR2B) and type I receptors ALK4/5, crucial in muscle mass regulation. Developed by researchers at Brigham Young University, this compound aims to treat muscle wasting disorders such as cachexia, sarcopenia, and muscular dystrophies by blocking pathways that negatively regulate muscle growth.
Key Advantages
- Orally administrable, offering ease of use compared to injectable treatments
- Cost-effective alternative to antibody therapies
- Targets specific receptors involved in muscle mass regulation, potentially offering more directed treatment
Problems Addressed
- Difficulties in treating muscle wasting disorders due to lack of effective oral medications
- High cost and accessibility issues associated with current antibody therapies
- Limited options for directly targeting the myostatin signaling pathway
Market Applications
- Treatment for cachexia associated with cancer, AIDS, and other chronic diseases
- Therapeutic option for age-related muscle loss (sarcopenia)
- Potential treatment for various muscular dystrophies
Additional Information
Technology ID: 2013-061
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 13 May, 2025
Connect with the Tech Transfer to:
- Meet with the technology manager
- Receive additional information
- Request a marketing plan report